$41.89
-2.9%Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
OMCL โข NASDAQ
| Omnicell, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.2B | 1.1B | 1.1B | 1.3B | 1.1B | 892.2M | 897M | 787.3M | 716.2M | 692.6M | 484.6M | 440.9M | 380.6M | 314M | 245.5M | 222.4M | 213.5M | 251.9M | 213.1M | 154.7M | |
GROSS PROFIT | ||||||||||||||||||||
(676.8M) | (641.2M) | (647.2M) | (707M) | (577.4M) | (478.9M) | (460.1M) | (415M) | (394.1M) | (378.8M) | (236.6M) | (207M) | (177.2M) | (143.5M) | (109.8M) | (104.5M) | (108.2M) | (123.2M) | (99.8M) | (69.2M) | |
508M | 471M | 499.9M | 589M | 554.7M | 413.3M | 436.9M | 372.3M | 322.1M | 313.8M | 247.9M | 233.9M | 203.4M | 170.6M | 135.8M | 117.9M | 105.2M | 128.6M | 113.3M | 85.5M | |
OPERATING INCOME | ||||||||||||||||||||
(496.4M) | (470.7M) | (519.3M) | (591.3M) | (465.1M) | (377.8M) | (358.6M) | (327.9M) | (316.3M) | (307.3M) | (202.7M) | (184.3M) | (168.1M) | (143.5M) | (119.6M) | (107.2M) | (103.2M) | (111.3M) | (95.1M) | (76.3M) | |
(408.6M) | (380.3M) | (426M) | (486.3M) | (389.4M) | (307.6M) | (289.9M) | (263.1M) | (250.3M) | (249.5M) | (167.6M) | (156.5M) | (139M) | (119.7M) | (97.5M) | (86.2M) | (85.7M) | (93.1M) | (80M) | (65M) | |
(87.7M) | (90.4M) | (93.3M) | (105M) | (75.7M) | (70.2M) | (68.6M) | (64.8M) | (66M) | (57.8M) | (35.2M) | (27.8M) | (29.1M) | (23.7M) | (22M) | (21M) | (17.6M) | (18.2M) | (15.1M) | (11.2M) | |
11.7M | 337K | -19.3M | -2.3M | 89.5M | 35.5M | 78.4M | 44.4M | 5.8M | 6.5M | 48.6M | 49.6M | 35.3M | 27.1M | 16.2M | 9.5M | 669K | 17.3M | 18.2M | 9.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(3.9M) | (4.5M) | (0.0) | (130K) | (22.4M) | (2.1M) | (5.8M) | (0.0) | (0.0) | (0.0) | (2.4M) | (1.1M) | (122K) | (29K) | (62K) | (4K) | (15K) | (15K) | (0.0) | (0.0) | |
8M | 20.4M | 14.8M | -130K | -22.4M | -2.1M | -4.4M | 0.0 | 0.0 | 0.0 | -2.4M | -1.1M | -270K | -51K | 204K | 420K | 604K | 3.4M | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -178K | -99K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-340K | 25.3M | -779K | -130K | -23.5M | -6.2M | -4.4M | -8.8M | -6.6M | -8.4M | -2.4M | -1.1M | -270K | -51K | -133K | 431K | 523K | 3.4M | 6.1M | 1.9M | |
11.3M | 25.6M | -20.1M | -2.5M | 66M | 29.3M | 73.9M | 35.6M | -879K | -1.9M | 46.2M | 48.5M | 35M | 27M | 16.1M | 10M | 1.2M | 20.7M | 24.3M | 11.2M | |
NET INCOME | ||||||||||||||||||||
(9.3M) | (13.1M) | (263K) | -8.1M | -11.8M | -2.8M | (12.6M) | -2.1M | -21.5M | -2.6M | (15.5M) | (18M) | (11.1M) | (10.9M) | (5.7M) | (5.1M) | (748K) | (8M) | -19M | (804K) | |
2.1M | 12.5M | -20.4M | 5.6M | 77.8M | 32.2M | 61.3M | 37.7M | 20.6M | 603K | 30.8M | 30.5M | 24M | 16.2M | 10.4M | 4.9M | 444K | 12.7M | 43.3M | 10.4M |
OMCL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | May 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 06, 2025 | September 30, 2025 | 2025 |
Continue your OMCL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.